skip to Main Content

September 21, 2022
The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation
Statement / Press
As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of…

August 23, 2022
Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci
Statement / Press
Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

August 23, 2022
Ten Principles for Access to Multi-disease Molecular Diagnostics: A Global Call to Action
Statement / Press
Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.

August 23, 2022
Treatment Action Group Adds Three New Board Members
Statement / Press
As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

August 5, 2022
Senior TB Project Associate
Treatment Action Group (TAG) is seeking a dynamic, highly motivated, and organized Senior TB Project Associate to support community engagement activities under the SMART4TB Project – a $200 million investment made by USAID to Support, Mobilize, and Accelerate Research for TB Elimination.

August 1, 2022
New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment
Statement / Press
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

July 31, 2022
1 / 4 / 6 x 24 Campaign Launched to Rally Energy, Political Will, Funding Needed to Fight Tuberculosis
Statement / Press
Against the backdrop of the COVID-19 pandemic and other concurrent global health, economic, social, and political crises, the 1 / 4 / 6 x 24 Campaign, launched during the AIDS conference in Montreal, seeks to improve TB treatment and prevention worldwide based on the latest medical innovations and to reignite…

July 25, 2022
1 / 4 / 6 x 2024
Webinar / Presentation
Inspired by the legacy of Dr. Paul Farmer, the 1 / 4 / 6 x 24 Campaign calls for the “staff, stuff, space, systems and support” necessary to make groundbreaking short-course TB prevention and treatment regimens accessible to all who need them as a human right by the end of 2024.

July 24, 2022
2022 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

July 18, 2022
TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast
Publication
In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.

July 8, 2022
Research in Action Awards 2022
Save the date for Tuesday, November 16, 2021! TAG’s 2021 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world. This year we’ll once again gather virtually…

July 1, 2022
Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline
Statement / Press
A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

June 23, 2022
Roundtable on Access to Multi-disease Molecular Diagnostics
Webinar / Presentation
On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify ways to leverage the availability of new multi-disease molecular diagnostic…

June 23, 2022
Treatment Action Group Statement on NYC DOHMH Monkeypox Vaccination Announcement
Statement / Press
In response to this morning’s announcement by the New York City Department of Health and Mental Hygiene (NYC DOHMH) that the DOHMH would open a temporary monkeypox vaccination clinic at the Chelsea Sexual Health Clinic in New York, Treatment Action Group’s Executive Director, Mark Harrington, and TAG HIV Project Director…

June 10, 2022
Consultancy to Expand Donor Country Fiscal Commitments for Tuberculosis R&D
TAG is seeking a consultant to advance strategic policy advocacy and resource mobilization efforts for TB R&D, specifically for new TB vaccines and by positioning TB within global efforts to curb anti-microbial resistance (AMR).

Back To Top